Replies to post #157623 on Elite Pharmaceuticals Inc (ELTP)

[richme]

I think the law of diminishing returns concerned units of production of the same product; that is why companies diversify. There is also supply and demand such that the law of diminishing returns would not matter if there is a limitless demand where every thing demanded could be sold. Assumption is that the price would remain constant so it is the next price that would determine if it is worth adding more costs.

[sharpei]

And WeeZuhl, what I think you may be implying, which you don't specify: 'How old is NH? Is he not focused on retirement at this stage and after putting himself through all the responsibility he bears as CEO?' 2018 buyout makes sense.

[no2koolaid]

Great post. What you are asking is a compound question that actually is formed by the last three paragraphs and I can answer it in a relatively short paragraph. While it does not mean I am right, it is a logical guess based on my view of M&A.

If we consider the Epic deal covers costs for ELI200 without dilution, and if we think the tech is plug and play, I think they need four products to prove to a big pharma firm that all is well enough with the tech to be bought. And, that is why it could be done before 2018. IMHO...

[IB_]

I agree, If Elite is going to find a buyer that will pay over $1.00 per share, it will likely be in late 2018 or 2019 as we all have learned to expect Delays in Elites business !!! Nasrat has just over a year before he can begin selling his shares as I understand it.


True Long,

IB_